Statistics

Total Visits

Views
A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC)1

Select a period of time:

Number of views in the range

Views
A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC)1

Views

Views
February 20261
Download CSV file
 untranslated
 untranslated

Top country views

Views
Nigeria1
 

Top cities views

Views
Lagos1